NCT00330382View on ClinicalTrials.gov

Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia

PHASE2CompletedINTERVENTIONAL
Enrollment

325

Participants

Timeline

Start Date

January 31, 1999

Primary Completion Date

July 31, 2010

Study Completion Date

May 31, 2013

Conditions
Lip and Oral Cavity CancerOral LeukoplakiaOropharyngeal CancerTongue Cancer
Interventions
DRUG

Bowman-Birk inhibitor concentrate

Given orally

OTHER

placebo

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

92868

University of California Medical Center At Irvine-Orange Campus, Orange

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00330382 - Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia | Biotech Hunter | Biotech Hunter